New hope for hepatitis c relapsers: triple therapy shows promise

NCT ID NCT00780910

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a triple-drug combination—telaprevir, peginterferon, and ribavirin—in 109 adults with genotype 1 hepatitis C whose infection returned after previous treatment. The goal was to see if the new regimen could clear the virus from the blood 24 weeks after treatment ended. Participants took telaprevir for 12 weeks plus the other two drugs for 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Telaprevir (MP-424) combined with peginterferon alfa-2b and ribavirin
What this could lead to: If successful, this combination could offer a more effective retreatment option for people with hepatitis C who relapsed after standard therapy, potentially clearing the virus.
What could go wrong: This is a small Phase 3 study (109 participants) and results may not apply to all patients. Side effects from the drugs can be significant, including anemia and depression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis C virus infection hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS C

Contacts and locations

Locations

Toranomon Hospital

Kawasaki, Takatsu-ku, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.